A few things have remained constant since the novel coronavirus outbreak was declared a pandemic: OHSU innovators have continued to meet new challenges and develop technologies with extraordinary creativity, startups and partnerships have formed to address unmet human health and wellbeing needs, and our innovation and entrepreneurial community at OHSU and regionally continues to grow stronger.

Our annual Research and Innovation Awards are another constant. We encourage you to read the Research and Innovation Awards publication that describes the innovations of the 2022 award recipients and recognizes the other many individuals who have contributed to impressive success this last year.

2022 Research and Innovation Awards recipients include Marcel Curlin, M.D., Hiroyuki Nakai, M.D., Ph.D., Fikadu Tafesse, Ph.D., and Dhanir Tailor, Ph.D. Additionally, Yali Jia, Ph.D., is recognized for her recent election as a Senior Member of the National Academy of Inventors.

Also recognized are new startups, inductees into the OHSU Chapter of the National Academy of Inventors, and 186 innovative investigators who have been creating technologies and moving ideas to market. Read the announcement.

Congratulations to all. We hope to host an in-person awards event next
OHSU Startup Company GoCheck aims to improve early diagnosis of ophthalmic diseases

Oregon Health & Science University’s (OHSU) startup company, GoCheck, has a clear mission to protect kids from preventable vision impairment and blindness. Based on foundational technology from OHSU faculty member David Huang, M.D., Ph.D., the company’s product, GoCheck Kids, utilizes a phone-based screening platform to provide instant and affordable early eye screening.

The video above tells the story of one family where the utilization of GoCheck Kids’ screening tool at a routine pediatric check-up led to the eventual diagnosis of the potentially fatal cancer, retinoblastoma. Read the full GoCheck company profile on OHSU Innovates to hear about the impact their screening tool is having on the lives of patients, and visit the GoCheck company website to learn more.
That's a wrap on Innovation Day 2022!

Thank you to everyone who presented and attended Innovation Day 2022 — what a great audience! The events below were a fantastic showcase of innovation happening at OHSU right now and a glimpse at where the innovation community is headed.

- **Paul R. Sanberg, Ph.D., D.Sc.,** president of the National Academy of Inventors (NAI), kicked off the day discussing his career journey as an entrepreneur, the programs and objectives of the NAI, and the importance of recognizing and rewarding innovation in academia.
- A Researcher’s Guide to Partnering with industry was a stimulating discussion between two OHSU collaborations, both stressing that communication is critical to develop attainable goals, overcome obstacles and work together to bring real-world changes to healthcare.
- The Startup Showcase offered a glimpse into both early and later-stage OHSU startup companies that are striving to improve the care and treatment of patients in Oregon and beyond. Read the [Portland Inno article](#) covering this panel.
• The Innovation Showcase highlighted new and emerging healthcare technologies being developed at OHSU and the brilliant inventors behind them.
• The closing keynote featured an important conversation on how to improve diversity, equity and inclusion in the innovation community and featured Graciela Cowger, J.D., CEO of Portland law firm Schwabe, Williamson and Wyatt, Aditi Martin, Ph.D. senior director of OHSU Collaborations and Entrepreneurship and Marguerita Lightfoot, Ph.D., associate dean at OHSU-PSU School of Public Health.

**FEATURED NEWS**

**OHSU startup company Promedix receives investment from Baxter through the mHUB MedTech Accelerator**

Promedix was one of four MedTech startups selected for an initial investment from Baxter as part of the mHUB Accelerator program. The company is developing HydraSense, a medical device that is designed to provide a rapid, accurate, and noninvasive assessment at the clinical bedside or remote care setting to help diagnose sepsis and monitor patient decline and response to treatment. This OHSU startup company was founded by David Sheridan, M.D., and Matthew Hansen, M.D., and received early funding from OHSU Innovates and the Oregon Clinical and Translational Research Institute through the Biomedical Innovation Program (BIP) and IDEA fund. For more information, read the [investment announcement](#) and visit the [Promedix company website](#).

**Inherent Targeting selected as a finalist for AOBIO**

OHSU startup Inherent Targeting was named a finalist in the Angel Oregon Life & Bioscience (AOBIO) program sponsored by the Oregon Entrepreneurs Network! Inherent Targeting was selected from a pool of Oregon life science startups to compete for investment from local angel investors. OHSU is proud to sponsor this program and the continued growth of the life sciences ecosystem in the region. Don’t miss Inherent Targeting’s pitch by CEO Connor Barth, Ph.D., at the AOBIO Finale May 26. Tickets are
available through www.oen.org.

Hear what drives OHSU scientists to innovate

Watch this video, which features interviews with OHSU scientists. Their passion comes through loud and clear as they discuss the thrill discovery brings, the comradery of the OHSU research community and the drive to improve people’s health and well-being.

Included are inventors from the OHSU Innovates community who are aiming to cure blood cancers, double the life of dental fillings, address mental health in teens, improve treatments for heart disease and much more. These scientists pack a lot of passion into this short video.

Pacific Northwest bioMedical Innovation Co-Laboratory (PMedIC) Spring 2022 Newsletter
The most recent edition of the Pacific Northwest bioMedical Innovation Co-Laboratory (PMedIC) quarterly newsletter is now available. You’ll find a new name and look, with the same mission. This newsletter also includes recent announcements related to the partnership, including awards and funding received on joint grant applications and pilot project grants.

New study one of first to compare effectiveness of sunscreen verses sun-protective clothing

Sancy Leachman, M.D., Ph.D., director of the OHSU Knight Cancer Institute’s Melanoma Program, and Elizabeth Berry, M.D., also a dermatologist at OHSU, recently collaborated with researchers at Columbia Sportswear to compare sun-protective clothing to sunscreen. The Columbia team tested the performance of four of Columbia’s Omni-Shade™ textiles engineered for sun protection against two commercial sunscreens, and recently published their findings in the journal Cancers.

“Dermatologists have long debated the pros and cons of sun-protective clothing and sunscreen, but we’re one of the first to compare the two head-to-head,” says Berry, assistant professor of dermatology in the OHSU School of Medicine and co-founder of the OHSU Multi-Disciplinary
Melanoma and Skin Cancer Clinic. “Our study showed that the tested fabrics provided superior UVB, UVA, and overall broad-spectrum protection when compared to two commercial sunscreens. These data show that clothing should be considered the cornerstone of sun protection.”

However, Berry still recommends using both clothing and sunscreen to protect your skin. “Sunscreen will always be important,” she says “especially on areas of the body such as the face and hands that are hard to cover with clothing.”

OHSU’s melanoma awareness campaign is ramping up for the full month of May and continuing until August. May is “Melanoma Awareness Month,” and we encourage everyone to look at their skin on “Melanoma Monday” (Mondays in May). Learn more about the War on Melanoma on OHSU Now and at War-on-Melanoma.

Disclosure: The Columbia Sportswear Company provided funding for the data collection and portions of the sun-protective clothing analysis. The OHSU Department of Dermatology and War on Melanoma provided salary support for the OHSU investigators.

ANNOUNCEMENTS

Anne Carlson, Ph.D., CLP, appointed as the new Associate Director of Technology Development and Licensing
Anne Carlson, Ph.D., CLP, has been appointed Associate Director of Technology Development and Licensing. In her new position, Anne will oversee the Technology Development and Licensing team, which manages the commercialization of OHSU innovations, including evaluation, intellectual property protection, marketing, and licensing. Since joining OHSU in 2015, Anne has worked closely with inventors to bring their innovative technologies to market, and was recognized in 2021 with a Deal of Distinction Award by the Licensing Executive Society.

---

Oregon Bioscience Association Inventory Survey: Research and Manufacturing Space

The Oregon Bioscience Association is conducting a survey to inventory space available and/or needed for life science labs, medical manufacturing and cleanrooms in Oregon and southwest Washington. With measurement of these capabilities, our region can achieve inclusion in national rankings of life science clusters, opportunities to attract new companies to the state, opportunities to grow existing businesses, and the ability to call for the creation of new investment tax credits. The survey closes May 30.

Take the survey.

---

PMedIC announces inaugural Innovation Grant recipients

Two teams of researchers led by Bill Messer, M.D., Ph.D., and Tejpal Gill, Ph.D., at OHSU, and PNNL scientists John Melchoir, Ph.D., and Ernesto
Nakayasu, Ph.D., were awarded funding to pursue joint collaborative projects for PMedIC. Read more on OHSU Now.

FEATURED EVENT

AOBIO Grand Finale May 26 at Amaterra Winery

The AOBIO Grand Finale & Innovation Showcase will be held on May 26, 3-7 p.m. at the new Amaterra Winery in Portland. The program will include a panel discussion with investors sharing their secrets for making good science investments, main stage pitches from all four finalist companies, the AOBIO Emerge Award presentation, a showcase of life and bioscience innovations happening in Oregon right now, and a special keynote from Absci founder, Sean McClain. At the end of the day the AOBIO investors will announce their selection for a collective angel investment, projected to be as much as $300,000. Read more details and get your tickets.

UPCOMING EVENTS

MAY 26

Angel Oregon Life & Bioscience Finale
<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>JUNE 1</td>
<td>PMedIC Seminar Series: Mass spectrometry-based single cell proteomics for</td>
</tr>
<tr>
<td></td>
<td>characterization of inner-ear sensory hair cells</td>
</tr>
<tr>
<td>JUNE 8</td>
<td>OEN June PubTalk: AOTECH PitchSLAM</td>
</tr>
<tr>
<td>JUNE 13-16</td>
<td>BIO International Convention: Start-Up Stadium</td>
</tr>
<tr>
<td>JUNE 14</td>
<td>TiE Oregon: Open mic night</td>
</tr>
<tr>
<td>JULY 19</td>
<td>Bio in the High Desert</td>
</tr>
<tr>
<td>JULY 23</td>
<td>Technology Association of Oregon: 2022 Party in the Pinot</td>
</tr>
</tbody>
</table>

**TECHNOLOGIES**

Featured Technologies Available for Licensing

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the [OHSU Technology Portal](#).

**OHSU 2531** - Software for automated identification and segmentation of perivascular spaces on MRI

**OHSU 2986** — Koala Kushion: an improved feeding positioner for infants

**OHSU 2798** - SARS-CoV-2 single domain antibody (nanobody) for the treatment of COVID-19

**OHSU 2825** - Cell-free RNA biomarkers capable of distinguishing cancer from premalignant disease
Newly Licensed or Optioned OHSU Technologies

Congratulations to the inventors of the below technologies, which were recently licensed or optioned to outside partners.

OHSU 1518 - QD Molecular Assay for Personalized Oncoprotein Detection in Leukemia (Brian Druker, Thomas Jacob, Tania Vu)

**OHSU 1771** - Materials from the BioLibrary

OHSU 1873 - Cell surface-labeling monoclonal antibodies for human pancreas, HIC3-2D12, DHIC5-4D9 (Craig Dorrell, Markus Grompe, Philip Streeter)

OHSU 2029 - Method of Discrete Counting of Individual Probes Yields Ultrasensitive Detection of Proteins in Cells (Thomas Jacob, Tania Vu)

OHSU 2639 - Monoclonal antibodies (mAbs) against human epithelial sodium channel (hENaC) (Isabelle Baconguis, Arpita Bharadwaj)

OHSU 2671 - Ferumoxytol as an MRI contrast agent (Rochelle Fu, Amy Huddleston, Lisa Muir, Edward Neuwelt, Bill Rooney, Gerda Teglassy)

**OHSU 2700** - A strong micro-promoter for AAV (Sunghee Chai, Markus Grompe)

OHSU 2727 - Novel monoclonal antibodies that recognize intestinal stem cell populations (Melissa Wong)

OHSU 2994 - A strong micro-promoter for AAV (Sunghee Chai, Markus Grompe)

U.S. Patents Issued

Congratulations to the OHSU inventors of the following recently issued U.S. patents.

**Patent 11,263,747** - Detecting avascular areas using neural networks
Patent 11,266,732 - Recombinant HCMV and RHCMV vectors and uses thereof

Patent 11,284,823 - Device and method for blood volume measurement

Patent 11,302,043 - Automated detection of shadow artifacts in optical coherence tomography angiography

Patent 11,305,015 - Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Patent 11,305,024 - Cross-linked polymer modified nanoparticles

Researchers in New Industry Funded Research Projects

Researcher/Description: Congratulations to the following OHSU PI's for entering into new industry-sponsored research projects.

Aaron Janowsky, Ph.D. - Study on fentanyl overdose

Daniel Marks, M.D., Ph.D. - Antagonists for Cachexia

Babak Nazer, M.D. - Artificial intelligence and machine learning for Intracardiac Echocardiography (ICE)

David Wilson, M.D. - Prospective observational study of patients with ophthalmological disease

Hiroshi Ishikawa, M.D. - Prospective observational study of patients with ophthalmological disease

Jon Hennebold, Ph.D. - Novel therapies for improving infertility treatments in women with diminished ovarian reserve
We welcome and appreciate the collaborative nature of organizations that want to be a part of the ongoing innovative and entrepreneurial efforts at OHSU. Thank you to our sponsors!

Questions? Contact us at techmgmt@ohsu.edu.

This monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute, School of Medicine and the Knight Cancer Institute.